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Abstract 
Investigation of therapy naïve human tumor and adjacent normal tissue biopsies demonstrated 
that expression levels of miRNAs are altered at and between stages of CRC. Targets of these 
altered miRNAs are members of the Insulin signaling pathways. Phosphorylation states of 
several molecules in the Insulin signaling pathways were altered between stages of CRC, and 
significantly the change in molecular phosphorylation state correlated with decreases in 
specific miRNAs that target them. This data establishes a direct relationship between de-
creased expression of specific miRNAs and increased phosphorylation events in the IGF-1 
pathway and identifies the IGF-1 pathway as a critical driver of colorectal cancer. 
The expression levels of 319 miRNAs and phosphorylation levels of major signaling proteins 
were determined. Interestingly, we observed that miRNAs were altered in expression and 
several signaling molecules were altered in phosphorylation levels at and between each stage 
of CRC. Furthermore, many of the miRNAs that are differentially expressed at each CRC 
stage were targeting these same signaling proteins identified to be altered in phosphorylation 
level. Thus, our studies define a subset of important miRNAs to classify CRC stage and a 
relationship between miRNA depression and elevated phosphorylation of IGF-1R pathway 
signaling molecules. 
Key words: miRNA, IGF-1R pathway, Phosphorylation events, and Colorectal cancer. 
Introduction 
Colorectal cancer has been identified as the cause 
of more than 50,000 deaths annually in the US alone 
and greater than 100,000 new cases will be diagnosed 
in  2010  according  to  the  National  Cancer  Institute.  
Within the past two decades several signaling path-
ways have been identified to be dysregulated in CRC 
and  within  the  last  10  years,  several  miRNAs  have 
been demonstrated to be biomarkers for the presence 
of disease. However to date, correlation of miRNAs 
with CRC stage is lacking. Since CRC progresses in 
distinctive stages, we hypothesized that differences in 
miRNA expression might exist that would better de-
fine  CRC  stage  and  delineate  the  importance  of 
dysregulated events. 
All cancers ultimately result from the deregula-
tion of genetic systems and one of the most powerful 
influences of these systems to have been uncovered 
within the past 10 years has been miRNAs. A brief 
scan of the literature reveals greater than 3000 publi-
cations  curated  within  NCBI  on  the  association  of 
Cancer and miRNAs. As our understanding of miR-
NAs increases we postulate that miRNAs may serve 
not only as an indicator of CRC but also as a direct 
effector of CRC.  
MiRNAs are short 19 – 25 nucleotide stretches of 
RNA that base pair with mRNA to form complexes 
prior to protein translation and thus halt the expres-
sion of proteins. miRNAs start as pre-miRNA in the 
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nucleus and are cleaved in the cytosol into functional 
miRNA by Dicer. miRNAs then interact with target 
mRNA via interaction with Argonaute 2 and GW-182 
[1]. The final fate of the mRNA, i.e. degradation or 
sequestration, is dependent upon factors that are still 
being elucidated. In either case mRNA translation is 
ultimately arrested. 
Colorectal  cancer  begins  with  the  unregulated 
cellular growth of aberrant crypt foci in the colon or 
rectum and progresses through four stages of devel-
opment. Stage I is classified as cancer in the mucosa 
and submucosa of the colon or rectum wall. At Stage 
II the cancer has progressed through the muscle layer 
and may have spread to nearby organs. Stage III is 
characterized  with  cancer  spreading  to  the  lymph 
nodes and Stage IV has been reached once the cancer 
has metastasized throughout the body. 
Signaling pathways of CRC show a high degree 
of crosstalk and incorporate multiple negative feed-
back controls. Important molecules in these pathways 
have  been  shown  to  be  altered  in  phosphorylation 
state in CRC and these events can  be explained by 
their roles in cell growth, differentiation, metabolism, 
and  metastasis  [2,3,4,5,6,7].  Correlation  of  miRNA 
alterations  with  molecular  signaling  has  been  de-
scribed in vitro and in vivo; however this relationship 
has not been thoroughly explored in human patient 
tumors. 
We obtained Tumor and Normal adjacent tissue 
of 23 CRC patients (see Fig. 1) who were therapy na-
ïve from Indivumed of Hamburg, Germany. All sam-
ples were obtained within 5 minutes of excision and 
flash frozen for storage and transport. All patient in-
formation  was  kept  confidential  in  keeping  with 
Pfizer  HIPAA  protocol.  Each  patient’s  consent  was 
obtained by Indivumed. Our research indicates that 
there is a strong correlation between alterations in a 
few miRNAs and CRC stage and progression. We also 
identify  that  kinases  that  activate  members  of  the 
IGF-1 pathways are significantly phosphorylated and 
this activation correlates with miRNA status. 
 
Fig. 1.  Sample Population by Stage  
Materials and Methods 
RNA isolation 
All RNA samples were prepared from 50mg of 
CRC  tumor  fragments.  Tissue  homogenization  was 
performed  in  Qiazol  (Qiagen)  and  extracted  with 
Chloroform. Total RNA was isolated with miRNEasy 
kit (Qiagen) and assessed for quality with qRT-PCR. 
qRT-PCR 
10ng of Total RNA was reverse transcribed with 
ABI’s TaqMan® miRNA reverse transcription kit (ABI 
part number 4366597). Briefly, miRNA specific stem 
loop  primers  are  extended  in  the  presence  of  total 
RNA for first strand synthesis. Following first strand 
synthesis,  TaqMan®  probes  were  used  in  real  time 
PCR for total RNA quality assessment.  sn/snoRNAs; 
RNU24,  RNU48  and  RNU49  (ABI  part  numbers 
4373379,  4373376  &  4373383  respectively)  were  uti-
lized to compare freshly isolated RNA from commer-
cially  available  Total  Distal  Colon  RNA  (ABI  part 
number AM6836) for relative expression levels.  
Real time PCR was performed with TaqMan® 2x 
PCR Mastermix, No AmpErase® UNGase (ABI part 
number 4324018).  
Luminex FlexmiR Human panel Assay 
Built upon capture bead technology; the assay is 
designed to measure miRNA abundance in a multi-
plex format by first identifying the capture bead type 
and  then  the  amount  of  miRNA  captured.  This  is 
achieved  through  fluorescent  illumination  of  the 
capture beads after hybridization with the total RNA 
sample.   
miRNA  targets  are  captured  by  LNA  (Locked 
Nucleic acid) probes attached to the bead and multi-
ple copies of only one miRNA target may be captured 
per bead.  
Samples are first enzymatically biotinylated and 
then combined with the capture beads for hybridiza-
tion.  The  captured  biotinylated  miRNA  are  treated 
with  a  Streptadvidin-PE  conjugate  for  fluorescent 
labeling  before  measuring  miRNA  levels.  Measure-
ments were made with the BioPlex 200. Capture bead 
dye ratios were measured to determine miRNA target 
specificity  (thus  gating)  and  then  a  PE  fluorescent 
intensity  was  measured  for  relative  abundance  per 
bead.  Normalization  of  relative  abundance  was 
achieved through the inclusion of 4 snoRNA capture 
beads per multiplexed sample.  
Protocol was performed per manufacturer’s in-
structions (Luminex part numbers: FlexmiR Human 
miRNA panel kit; BG-FMIR-H20-8.0 and Labeling kit 
BG-FMIR-L50).  In  brief,  2.5ug  of  each  sample  was  Journal of Cancer 2011, 2 
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analyzed for 319 miRNAs and 4 snoRNAs. The Bio-
Plex  200  instrument  was  calibrated  and  validated 
prior  to  each  assay  run  per  manufacturer’s  instruc-
tions.  
BioRad 17plex Phosphoprotein detection As-
say 
To detect the phosphorylation states of multiple 
kinases  simultaneously  we  utilized  the  BioRad 
17-plex  capture  bead-based  technology.  Measure-
ments were made on the BioPlex200. Phosphorylation 
of analytes detected in this assay are as follows;  
p-Akt  (Ser473),  p-ATF-2  (Thr71),  p-ERK1/2 
(Thr202/Tyr204, Thr185/Tyr187), p-GSK3Α/β(Ser21/Ser9), 
p-Histone  H3  (Ser10),  p-HSP27  (Ser78),  p-IGF-IR 
(Tyr1131), p-IRS-1 (Ser636/Ser639), p-JNK (Thr183/Tyr185), 
p-MEK1  (Ser217/Ser221),  p-PDGF  Receptor  β  (Tyr751), 
p-p38 MAPK (Thr180/Tyr182), p-p53 (Ser15), p-p70 S6 
Kinase (Thr421/Ser424), p-p90RSK (Thr359/Ser363), p-Src 
(Tyr416),  p-Stat3 (Tyr705)  
Samples  were  lysed  according  to  Bio-Plex 
Phospho  17-Plex  Assay  procedures  (Bio-Rad  Cat# 
X70SMXL3DU  and  Document  #  4110018  Rev  C). 
Sample protein levels were determined by Pierce BCA 
assay  levels  and  diluted  to  500ug/ml  each.  25ul  of 
each sample lysate and assay controls were measured. 
Results 
Alterations in miRNA expression 
We observed alterations in expression levels of 
130 miRNAs when comparing Tumor to Normal lev-
els  at  and  between  stages  of  CRC.  (See  Table  1  for 
expression  profiles).  Only  significant  data  are  re-
ported and all are based upon unpaired t-tests with 
significance  assigned  by  p  <0.05.  Several  miRNAs 
showed dysregulation at multiple stages when com-
pared to their normal expression level. Let-7b, Let-7e, 
206, 302c*, 324-5p26, 330, 370, 376b, 490, 500, 516-5p, 
517*, 518a-2*, 518b, 518c*, 518f*, 526a, 526b, and 527 
were  all  down  regulated  at  stages  II,  III,  and  IV 
whereas only miR-21 was significantly up regulated 
at stages II, III, and IV. A smaller subset of 12 miRNAs 
were  depressed  in  tumor  expression  levels  at  all 
stages of CRC; miRNAs 138, 143, 145, 150, 192, 194, 
202, 320, 382, 503, 519e*, and 526c. Comparisons be-
tween each stage revealed that in most instances with 
the progression of CRC stage few significant altera-
tions  were  observed  although  significant  changes 
were  observed  when  comparing  tumor  to  adjacent 
normal  tissue.  The  significant  finding  was  that  the 
majority of altered miRNAs targeted critical signaling 
nodes in the Insulin signaling pathway. 
IGF-1 plays a role in CRC and studies show [8] a 
correlation between certain SNPs in IRS-1 and CRC 
[9]. We investigated the signaling events that would 
better delineate the role of IGF-1R signaling in CRC. 
To  this  end  we  analyzed  17  signaling  molecules 
known  to  be  associated  with  oncogenesis  and  the 
IGF-1R signaling pathway from 23 patients at differ-
ent CRC stages who were naïve for cancer therapies. 
Phosphorylation states of signaling molecules 
across CRC stage and correlations to miRNA 
alterations 
An  antecedent  of  Insulin  signaling  is  ligand 
binding to the IGF-1 receptor. IGF-1R is a tetrameric 
transmembrane  protein  of  the  Insulin  family  of  re-
ceptors. Upon binding of Insulin, IGF-1 or IGF-2 to the 
IGF-1 receptor, a signaling cascade is put in motion 
resulting in increased gene activation, cell cycle pro-
gression,  cell  growth,  differentiation,  and  an  an-
ti-apoptotic  effect.  These  events  follow  two  distinct 
arms of signaling pathways with crosstalk and nega-
tive  feedback  loops  creating  a  complex  network  of 
communication within the cell. Down one arm is the 
PI3K/Akt  pathway  and  down  the  other  is  the 
Ras/MAPK pathway (Fig. 2). 
IGF-IR  
IGF-1 and IGF-II are two principal ligands of the 
IGF-1R and both have been shown to be upregulated 
in cancer [10] thus affecting proliferation, differentia-
tion,  and  metastasis.  Upon  ligand  binding,  IGF-1R 
undergoes autophosphorylation of three critical tyro-
sine residues; Y1131, 1135, & 1136. These events result 
in the recruitment and potential tyrosine phosphory-
lation of IRS-1, IRS-2, Shc, and Grb-10 all known to 
effect  oncogenic  processes  [10].  Both  the 
PI3K-Akt-mTOR and Raf-MEK-MAPK pathways are 
thought to be two important downstream signaling 
pathways regulating oncogenesis.  
Each  signaling  cascade  takes  a  divergent  path 
with  some  cross  talk  evident.  We  found  several  of 
these signaling proteins to be altered in phosphoryla-
tion level between stages of CRC. We measured Y1131 
phosphorylation of IGF-1R as an indication of recep-
tor activation.  
Our data shows that as the stage of CRC pro-
gresses there is a significant increase from stages II to 
III and stage II to IV in Y1131 phosphorylation (Fig. 3). 
In colon tissue the over-expression of IGF-IR in 
tumor vs. normal is striking [11] since under normal 
physiological conditions the expression and activation 
of IGF-IR is tightly controlled.  
miRanda, a miRNA target prediction algorithm 
employed through the online resource microRNA.org  Journal of Cancer 2011, 2 
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[12,13,14,15],    identifies  254  miRNAs  to  potentially 
target  IGF-1R.We  measured  a  total  of  102  of  these 
miRNAs. Within our data set 47 of these miRNA are 
significantly altered in expression. (See Table 1 for all 
alterations).  It  is  notable  that  a  correlation  of  de-
pressed  miRNA  expression  and  increased  signaling 
molecule phosphorylation is often evident and, as we 
will show, will be a reoccurring theme throughout our 
research report. 
Table 1. Significant alteration of miRNA in CRC. Unpaired t-tests p-values < 0.05 reported in gold, Average tumor levels – 
Average Normal levels at each stage in red (increasing) and green (decreasing) and their respective targets in the IGF-1R 
signaling pathway. 
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IRS-1( IRS1)   
Of  the  signaling  molecules  interacting  with 
IGF-1R, IRS-1 has been proposed to play a pivotal role 
in cancer [16]. Originally identified as a signaling in-
termediate of Insulin receptor, it is now considered 
one of the most prominent molecules in the PI3K/Akt 
arm of IGF-1R signaling. Following docking to ligand 
bound  IGF-1R,  IRS-1  may  become  tyrosine  phos-
phorylated,  and  lead  to  downstream  activation  of 
several  canonical  (IR/IGF-1R  signaling)  or  non  ca-
nonical pathways (non IR/IGF-1R signaling; e.g. cy-
tokines, integrins, and hormones). The docking to IR 
or IGF-1R and subsequent tyrosine phosphorylation 
of  IRS-1  leads  to  the  activation  of  the  downstream 
signaling molecule, PI3K, and subsequent recruitment 
and phosphorylation of Akt by PDK1. The over ex-
pression  of  IRS-1  has  been  observed  in  numerous 
cancers [17] and its activation after docking to IGF-1R 
through Y950 recorded in only a few articles [18,19]. 
IRS-1 tyrosine phosphorylation was however identi-
fied in 27 of 34 different tumors in Breast Cancer [20] 
and in Colon cancer cell lines HT-29 [21] and CT-26 
[22].  In  each  study  tyrosine  phosphorylation  was  Journal of Cancer 2011, 2 
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measured by pan tyrosine Abs.  However there are 
several phosphorylation sites on IRS-1 and not all are 
activation signals. Phosphorylation of Serines 636/639 
by mTOR [23] and through a p70 S6 kinase mediated 
mechanism  [24,25]  leads  to  IRS-1  inactivation.  We 
measured S636/639 phosphorylation and found it to 
be increasing from stages I to III, I to IV, II to III, and II 
to IV (Fig. 3). 
Much  research  has  identified  a  negative  feed-
back system in the PI3K/Akt pathway [26]. This neg-
ative  feedback  involves  the  action  of  mTORC1, 
downstream  of  Akt.  Upon  phosphorylation  of 
mTORC1 it in turn phosphorylates p70 S6 kinase re-
sulting  in  RPS6  activation  and  increased  protein 
translation. However an alternate event, p70 S6 kinase 
phosphorylation  of  IRS-1  on  S636/639,  could  also 
occur resulting in decreased IGF-1R signaling. 
We  observe  a  significant  increase  across  the 
stages of CRC in Serine 636/639 phosphorylation (Fig. 
3), which as stated before is an inhibitory signal. This 
is not to say that all downstream signaling has been 
entirely  inhibited,  but  that  as  CRC  progresses  the 
negative feedback loops are increasingly signaling for 
IRS-1 to deactivate.   
Given that little has been studied on the phos-
phorylation state of IRS-1 in CRC these results should 
be of great interest for future research. The negative 
regulation of IRS-1 is well documented [20, 27] and 
our data suggests that as CRC progresses the negative 
feedback  loops  regulating  IRS-1  signaling  are  still 
active.  As  to  the  over  expression  of  IRS-1  in  CRC, 
miRanda identifies 56 miRNAs that are predicted to 
target IRS-1. We measured 26 and found 9 to be sig-
nificantly depressed.  
Akt (AKT1, AKT2, PKB) 
Akt  has  been  established  as  a  major  signaling 
node in numerous pathologies including cancer [28]. 
This is rooted in the elevated Akt levels found in tu-
mor tissue eliciting inhibitory effects on proapoptotic 
signaling events, activating cell proliferation, and cell 
growth [29]. Akt is a serine/threonine kinase whose 
actions are brought about through a variety of phos-
phorylation  sites.  Initially  Akt  is  partially  activated 
via the IGF-1R/PI3K signaling pathway by PDK1 at 
T309, however it is S473 phosphorylation by mTOR 
and specifically the mTORC2 complex that results in 
maximal  activation.  Upon  phosphorylation  of  S473, 
Akt can activate or inhibit numerous signaling mole-
cules in colon cancer [30, 31]. Of growing importance 
are the signaling molecule mTOR and the signaling 
cascade it regulates via two very different complexes, 
mTORC1  and  mTORC2.  Akt  has  been  shown  to 
phosphorylate  mTOR  via  PRAS40,  a  component  of 
mTORC1.  Further  downstream,  mTOR  phosphory-
lates p70 S6 kinase (T389), a regulator of Ribosomal 
Protein S6 (RPS6) responsible for mRNA translation, 
and has been proposed to signal via 14-3-3 (tyrosine 
3-monooxygenase), a required protein in Raf signal-
ing, to inhibit IRS-1 in a negative feedback loop [32].
 
 
Fig. 2. Phosphorylation pathways adapted from KEGG (50)(51). Cross talk of IGF-1R in Colorectal cancer. Closed arrows 
– activation via phosphorylation, Open arrows –inhibition via phosphorylation.  Journal of Cancer 2011, 2 
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Fig. 3. Phosphorylation events in the IGF-1R signaling pathway of CRC tumor samples.  One Way ANOVA significance 
reported as P<0.05 and unpaired t-tests to delineate significant alterations, p< 0.05 between stages of CRC.  Journal of Cancer 2011, 2 
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Our data shows significant increases in Akt S473 
phosphorylation levels when comparing stage I to IV 
and  stage  II  to  IV  (Fig.  3).  The  fact  that  Akt  S473 
phosphorylation is elevated with CRC progression is 
not surprising given its role in cell cycle progression, 
cell  growth,  protein  synthesis,  and  survival.  As  to 
miRNA regulation, miRanda predicts 85 miRNAs to 
target  Akt.  We  measured  33  of  these  miRNAs  and 
found  14  significant  decreases  between  tumor  and 
normal.  
GSK3α/β (GSK3A and GSK3B) 
GSK3α/β is a serine/threonine kinase known to 
play a role in several signaling pathways including 
the  Wnt/  β-catenin,  Hedgehog,  Notch,  and  Insulin 
pathways  [33].  In  its  non-phosphorylated  state  it 
functions  as  a  negative  regulator  of  Glycogen  syn-
thase and eIF2B. Additionally, its phosphorylation of 
the β-catenin/axin/APC complex results in the stabi-
lization of axin, targeting of β-catenin for ubiquitina-
tion, and subsequent negative regulation of gene ex-
pression. 
GKS3α/β  has  multiple  phosphorylation  sites 
and  among  these  are  S9  (β)  &  S21  (α).  Upon  their 
phosphorylation, GSK3α/β becomes inactive leading 
to the activation of Glycogen synthase and eIF2B. This 
S9/S21  phosphorylation  has  been  shown  to  act 
through the Insulin signaling pathway by Akt, having 
a variety of effects on downstream signaling [34].  
Inhibition of GSK3α/β results in Glycogen syn-
thesis,  up  regulation  of  protein  synthesis  by  eIF2B, 
and gene transcription of such oncogenes as Cyclin 
D1. Furthermore inactivation of the Forkhead family 
of transcription factors and TSC2 add to GSK3α/β’s 
role  in  cell  growth,  differentiation,  and  metastasis 
independent of β-catenin. Our data shows a signifi-
cant  increase  in  phosphorylation  of  S9/S21when 
comparing stages I – II, stages II – III, and a significant 
decrease between stages III – IV (Fig. 3). The increase 
in  Akt  S473  phosphorylation  shown  above  and  an 
increase  in  p70  S6  Kinase  phosphorylation,  to  be 
shown  later,  explain  the  increase  in  S9/S21  phos-
phorylation of GSK3α/β but how does this contribute 
to CRC? 
These  inhibitory  events  between  stages  I  to  II 
and  II  to  III  might  be  explained  in  recent  studies 
linking GSK3α/β to cell cycle checkpoint bypass and 
metastasis. In these studies GSK3α/β is reported to be 
inhibited in a number of tumor types. Kang et al. [35] 
establish  that  active  GSK3α/β  negatively  regulates 
Cdc25a, a phosphatase important in cell cycle transi-
tion that is over expressed in a number of cancers. As 
GSK3α/β  becomes  phosphorylated  and  thus  inacti-
vated, Cdc25a becomes activated and unchecked. The 
decrease in phosphorylation between stages III to IV, 
although  surprising,  may  be  explained  simply 
through the need for energy. As the progression of 
CRC  reaches  its  final  stages,  other  mechanisms  en-
gage to arrest Glycogen synthesis and free up glucose 
stores  for  an  increase  demand  for  energy  brought 
about  by  increased  cell  growth,  proliferation,  and 
differentiation.  As  to  miRNA  expression,  miRanda 
predicted  345  miRNAs  that  target  GSK3α/β.  We 
measured 81, 29 of which were all significantly de-
pressed in CRC. 
p70 S6 Kinase (RPS6KB1, S6K1) 
p70S6Kinase (S6K1) is a member of the Riboso-
mal S6 Kinase family that plays an important role in 
cell proliferation, cell cycle progression, cell size, and 
gene translation.  It is well documented to be upreg-
ulated in many tissue types and markedly so in colo-
rectal tumors [36]. The main upstream activator of p70 
S6 kinase is mammalian target of rapamycin (mTOR) 
via the PI3K-Akt signaling pathway. It is specifically 
mTORC1 that has been demonstrated to interact with 
p70 S6 kinase, phosphorylating T421/S424 and T386 
regulating various downstream responses. The most 
direct of these responses is its activation of RPS6 and 
subsequent  increased  protein  translation.  This  of 
course results in increased proliferation, growth, and 
survival. However, as stated previously, p70 S6 kinase 
has an alternate pathway that it may orchestrate. In-
sulin signaling has been shown to be negatively reg-
ulated  via  IRS-1  inhibition  as  a  direct  result  of  an 
Akt/mTORC1/p70 S6 kinase pathway.  p70 S6 kinase 
directly  binds  to  and  phosphorylates  IRS-1  via  two 
different  serine  residues,  S1101  and  S270.  Upon 
binding,  IRS-1  activity  has  been  shown  to  be  de-
creased, which is associated with an increase in S636 
phosphorylation of IRS-1. Our data shows that p70 S6 
kinase is also significantly increasing in its phosphor-
ylation state across stages I to III, and II to III, but de-
creasing between stages III to IV (Fig. 3). Given the 
interaction  of  p70  S6  kinase  and  IRS-1,  this  data 
strengthens our argument that the negative regulation 
of  insulin  signaling  in  CRC  remains  intact.  The  in-
creases observed between stages I to III and II to III 
are  in  good  agreement  with  the  above  argument 
however the decrease observed between stages III to 
IV require further consideration. What is striking is 
that  molecules  known  to  be  interacting  within  the 
Insulin signaling pathway are phosphorylated in ac-
cordance with each other. As we observe the increases 
in p70S6 kinase and highlight the inhibition of IRS-1 
we see an appropriate increase in IRS-1 S636 phos-
phorylation and as we observe a decrease in p70S6 
kinases between stages III to IV we also see, albeit not  Journal of Cancer 2011, 2 
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significant,  a  decrease  in  IRS-1  phosphorylation  be-
tween the same stages. An argument could be made 
where there is a switch that is engaged at the later 
stages  of  CRC  where  negative  regulation  of  the 
IGF-1R pathway is no longer supported and evasion 
of  apoptosis  and  increased  protein  translation  are 
forgone for an increase in cell growth and differentia-
tion. (See Fig. 2) 
To further complicate matters Julien et al [37]. 
suggests an even more intriguing role for p70 S6 ki-
nase. They propose that the activation of p70 S6 ki-
nase via mTORC1 results in the phosphorylation of 
Rictor, a component of mTORC2, on T1135 and this in 
turn signals increased Akt and GSK3α/β phosphory-
lation.  
Thus, in Julien et al.’s research [37] we not only 
have  a  novel  interplay  between  mTORC1  and 
mTORC2 but we also have a plausible explanation for 
our  results  of  increased  Akt  phosphorylation  and 
GSK3α/β. In our miRNA analysis we show that de-
creased expression of 36 miRNAs, predicted by mi-
Randa to target p70 S6 kinase, reasonably explains at 
least in part the over expression of p70 S6 kinase in 
CRC and plausibly its excessive phosphorylation. 
Overall miRanda predicts 262 miRNAs that tar-
get p70 S6 kinase. We measured 114, finding 37 sig-
nificantly altered. 
MEK1 (MAP2K1)  
MEK1  or  Mitogen-activated  protein  kinase  ki-
nase 1 is a Threonine/Tyrosine kinase member of the 
Ras oncogene signaling pathway. Ras becomes acti-
vated via IGF-1R signaling through SHC, an alternate 
intermediate signaling molecule that docks to IGF-1Rs 
activation loop via its PTB domain. Upon phosphor-
ylation of SHC, recruitment of Grb2 and SOS lead to 
the activation of Ras followed by subsequent activa-
tion  of  Raf.  It  is  Raf  that  activates  MEK1  through 
phosphorylation of S217/S221. This activation leads 
to  further  downstream  signaling  that  regulates  cell 
proliferation,  differentiation,  and  growth  [38].  Our 
data  shows  significant  increases  in  phosphorylation 
when comparing stages I to IV and II to III. (Fig. 3) 
As  for  the  miRNA,  miRanda  predicts  that  194 
miRNAs target MEK1. We measured 54 and observed 
that 21 were down regulated with CRC progression. 
The increase in MEK1 phosphorylation with the ad-
vancement of CRC is not surprising given the role of 
MEK1 in the MAPK cascade and together these two 
pieces of data provide further implication as to the 
inverse  relationship  of  miRNA  to  phosphorylation 
events. 
ERK1/2 (MAPK3/MAPK1) 
Extracellular signal related kinases 1 and 2, also 
known  as  MAPK3  and  1  respectively,  are  critical 
molecules  in  the  Mitogen-activated  kinase  cascade. 
Together these two proteins are responsible for me-
diating  the  MAPK  signaling  cascade  and  the  phos-
phorylation of a host of transcription factors such as 
Elk1,  CREB,  and  c-myc.  They  also  activate  further 
downstream signaling molecules leading to the acti-
vation  of p90RSK, JNK, and p38 MAPK, regulating 
cell growth, differentiation, motility, and cytoskeleton 
remodeling.  
The significant increase between stages I to III is 
expected given the multiple roles it plays in cellular 
signaling  whereas  the  significant  decrease  between 
stages III to IV was surprising. This decrease however 
suggests that in later stages of CRC this pathway is 
being  placed  in  check  somehow.  Reviewing  the 
miRNA  responsible  for  regulating  ERK1/2  in  our 
data set informs us that the only mRNA that is tar-
geted  by  miR-21  is  ERK1/2.  Our  data  shows  that 
miR-21 is consistently increased compared to normal 
tissues at stages II, III, and IV. Given the evidence we 
have so far shown regarding the number of miRNA 
depressed resulting in an increased phosphorylation 
of their targeted signaling molecules it is interesting to 
propose that here miR-21’s elevation may be respon-
sible  for  the  decreased  phosphorylation  of  ERK1/2 
from stages III to IV (Fig. 3). 
Overall miRanda predicts a total of 249 miRNA 
target  ERK1/2  (MAPK3  and  MAPK1  combined) 
where we measured 58 and observed 20 to be altered. 
11 of these were significantly depressed at stage IV, 
miR-21  significantly  elevated,  and  the  remaining  8 
unaltered at stage IV when compared to normal lev-
els. 
JNK (MAPK8) 
c-jun N-terminal kinase 1, another member of the 
MAPK cascade is directly phosphorylated by ERK1/2 
to  activate  a  number  of  downstream  transcription 
factors regulating protein translation. We observed a 
significant decrease between stages I to II followed by 
a  significant  increase  between  stages  II  to  III  of 
T183/Y185  phosphorylation  (Fig.  3).  We  did  not 
measure any miRNA predicted by miRanda to target 
JNK. 
p38 MAPK (MAPK14) 
p38 MAPK also known as MAPK14, is also, as its 
name  implies,  a  member  of  the  MAPK  cascade  of 
signaling molecules. It too is responsible for the reg-
ulation of cell cycle and proliferation. It is activated 
via direct phosphorylation of T180/Y182 by ERK1/2 
and exerts its effects through direct interaction with 
transcription factors like  ATF2, cell cycle regulators  Journal of Cancer 2011, 2 
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like Cdc25b, and tumor suppressors like p53. We ob-
serve a significant increase in T180/Y182 phosphory-
lation between stages II to III followed by a significant 
decrease from stages III to IV (Fig. 3). (Of interest, no 
significant  alterations  were  observed  across  CRC 
stage for p53) p38’s (MAPK14) role in Insulin signal-
ing  is  still  quite  poorly  understood  however  it  has 
been linked to IGF-1’s antiapoptotic regulation [39]. 
Thus our data is again in agreement with our argu-
ment of a pathway switching from antiapoptotic and 
increased protein translation in the earlier stages of 
CRC to more growth and differentiation in the later 
stages of CRC. As seen with IRS-1, GSK3α/β, p70 S6 
kinase, and p90RSK, an initial increase in phosphor-
ylation directs IGF-1 signaling (see Fig. 2) toward in-
creased  protein  synthesis  and  antiapoptotic  mecha-
nisms  with the  onset of CRC and as the pathology 
progresses a switching of pathway mechanism occurs 
which is evident by the decreased phosphorylation of 
these same signaling  molecules toward growth and 
differentiation mechanisms. 
ATF2 
Activating  transcription  factor  2  is  a  transcrip-
tion factor that upon phosphorylation of T69 and T71 
is  capable  of  both  homo-  and  hetero-dimerization 
with family members of the Jun/Fos regulators. This 
range of interactions affords ATF2 roles in cell cycle 
regulation, growth, differentiation, and apoptosis. 
The exact nature of signaling events in CRC is 
poorly defined however it has been demonstrated that 
it is dependent  on ERK, JNK, and p38 MAPK [40]. 
Within our study we observed each; ERK, JNK, and 
p38  MAPK  to  be  significantly  increasing  with  CRC 
stage. Both JNK and p38 MAPK increase significantly 
between stages II to III and ERK  increasing signifi-
cantly from stages I to IV. Both ERK and p38 MAPK 
are decreasing significantly between stages III to IV 
with a trending (unpaired t-test, p  = 0.07) decrease 
observed for JNK between III to IV (Fig. 3). Our data is 
only looking at T71 phosphorylation however it has 
been previously shown in CRC that both T69 and T71 
are phosphorylated through these mechanisms [41]. 
What we have delineated is the specific stage at which 
these events occur.  
miRanda predicts that 162 miRNA target ATF2 
and we measured 46 of these. Of these 46 we observed 
13 significant alterations where 2 were increasing at 
stage III and the remainder significantly decreasing at 
various stages of CRC. 
p90RSK (RPS6KA1, RSK1) 
p90RSK (RSK1) is a member of the Ribosomal S6 
kinase family with roles in cell growth, motility, sur-
vival and proliferation. It is well documented to be 
upregulated in Colon tumor tissues and has been as-
sociated with both Breast and Pancreatic cancers [42].  
As epithelial cells undergo transformation they 
lose  their  basal  membrane  survival  cues.  RSK1  has 
been identified as a pivotal activated kinase inducing 
autocrine  loops  that  permit  cell  motility  and  inva-
siveness of transformed epithelial cells [43]. It is also 
established that RSK1 phosphorylates TSC2 [44], in-
hibiting its tumor suppressor function by activating 
the mTOR signaling pathway and promoting transla-
tion. Our data shows that RSK1 is significantly altered 
in  phosphorylation  state  between  all  stages.  Phos-
phorylation of p90RSk is significantly increasing be-
tween stages I to II, I to III, I to IV, and II to III fol-
lowed by a significant decrease from stage III to IV 
where stage IV is still significantly higher than stage I 
(Fig. 3). 
As  a  downstream  effector  of  the 
Ras/ERK/MAPK signaling cascade, p90RSK is a di-
rect substrate of ERK1/2 [44]. As shown previously, 
ERK1/2 also significantly decreased in phosphoryla-
tion level from stage III to IV and this is reflected here 
with p90RSK phosphorylation level.  
miRanda predicts 94 miRNA target p90RSK. We 
measured 46 and observed 21 altered, of which, with 
regards  to  stage  IV,  only  7  were  significantly  de-
pressed and the remainder unaltered. 
Discussion 
The phosphorylation levels of IGF-1R, IRS1, Akt, 
GSK3αβ,  p70  S6  kinase,  MEK1,  ERK1/2,  JNK,  p38 
MAPK,  and  ATF2  all  showed  significant  levels  of 
dysregulation  across  stages  of  CRC.  Negative  feed-
back  systems  and  miRNA  expression  changes  are 
supported as regulatory elements of this dysregula-
tion and shed light on the connection between miRNA 
and signaling events in IGF-1R signaling in CRC. The 
observation  that  IRS-1,  GSK3α/β,  p70S6  kinase, 
ERK1/2, MAPK14, and p90RSK all show significant 
increases in phosphorylation across stages I, II, and III 
followed by a decrease at stage IV implies that a shift 
of mechanisms is at play and warrants further inves-
tigation.  We  suggest  that  this  shift  is  from  protein 
synthesis  and  evasion  of  apoptosis  to  growth  and 
differentiation.  Furthermore  we  show  that  miRNAs 
targeting  these  signaling  molecules  are  downregu-
lated  when  an  increase  in  phosphorylation  is  ob-
served and normalized as decreased phosphorylation 
is  observed.  Together  these  observations  make  a 
strong  implication  of  miRNAs  as  an  underlying 
mechanism in dysregulation at the heart of CRC. 
miRNAs  currently  being  considered  as  valid 
biomarkers  include  both  upregulated  “oncomiRs”  Journal of Cancer 2011, 2 
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and down regulated tumor suppressor miRNAs. This 
list  is  continually  growing  but  includes  miR-18a, 
miR-21, miR-30a-3p, miR-30a-5p, miR-126, miR-135b, 
miR-143, miR-145, miR-155, miR-183, & the let-7 fam-
ily [45, 46, 47, 48, 49]. With respect to Colorectal Can-
cer we would add to this list the following miRs al-
tered at all stages of CRC and  based upon their mul-
tiple  targets  in  the  IGF-1R  signaling  pathway; 
hsa-miR-138,  hsa-miR-194,  hsa-miR-320,  and 
hsa-miR-382. 
Of  the  130  miRNAs  observed  to  be  altered  in 
CRC  we  observed  a  total  of  94  miRNAs  targeting 
signaling  molecules  in  the  IGF-1R  pathway.  This 
number  is  more  impressive  when  it  is  appreciated 
that 45 of these miRNAs target 3 or more signaling 
molecules in our analysis. This suggests that miRNAs 
might  also  lead  to  identification  of  other  signaling 
molecules previously unidentified in pathology to be 
causative. As the predictive power of miRanda and 
other  algorithms  increases,  molecules  that  have  not 
previously  been  associated  with  a  disease  or  mole-
cules  that  have  not  been  assigned  a  function  at  all 
might be predicted to have some therapeutic value. 
Taken  together  our  research  identifies  a  subset  of 
miRNAs that can serve as biomarkers of CRC stage 
and  significantly  it  points  to  the  critical  role  of  the 
IGF-1  pathway  in  CRC  progression.  These  studies 
also provide rationale for anti-IGF-1 targeted therapy 
in CRC. 
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